Science and Tech Part 4: Genome India and Bio-E3

In one line: Science and Technology Part 4: The bioeconomy file covers the Genome India Project, the Covid vaccine record, the CAR-T breakthrough, and the policy stack.

In fact, the bioeconomy file covers the Genome India Project, the Covid vaccine record, the CAR-T breakthrough, and the policy stack (BIRAC, Bio-E3 2024). In fact, this note assembles the cluster in exam ready form.

Quick Answer: The bioeconomy file covers the Genome India Project, the Covid vaccine record, the CAR-T breakthrough, and the policy stack (BIRAC, Bio-E3 2024). Moreover, this note assembles the cluster in exam ready form.

Table of Contents.

1. The Genome India Project
2. The Vaccine Record and Bio-Manufacturing
3. The Frontier: CAR-T, CRISPR Therapies
4. Therefore, the Policy Stack: BIRAC and Bio-E3
5. The Regulation and Ethics Layer
6. How Exams Probe This Topic
7. Quick Revision: One-Glance Facts

1. The Genome India Project.

• Meanwhile, genome India Project (GIP) — launched 2020 by the Department of Biotechnology , a consortium of 20 institutions (IISc Bengaluru coordinating). Moreover, goal: whole genome sequencing of 10,000 Indians — the target was completed in early 2025. With the dataset released to researchers through controlled access — the current milestone to cite.
• As a result, india’s population holds ~4,600 distinct groups with heavy endogamy — founder effects enrich disease specific variants that global reference genomes miss. Therefore, indian data improves variant interpretation, disease risk prediction and pharmacogenomics (drug response) for Indians.
• The global context. In other words, human Genome Project (1990-2003, first draft); the complete T2T genome (2022); the UK’s 100. Meanwhile, 000 Genomes Project — India’s dataset is the largest single country effort focused on such genetic diversity.
• Notably, precision medicine (targeted cancer therapy, drug dosing), rare disease diagnosis (India’s ~7 crore rare disease patients), population health and ancestry studies, forensics.

2. The Vaccine Record and Bio-Manufacturing.

• Indeed, covaxin (Bharat Biotech’s inactivated virus vaccine, co developed with ICMR). As a result, covishield (Serum Institute’s licensed AZ vaccine — SII is the world’s largest vaccine maker, supplying ~60% of global children’s vaccines). ZyCoV-D (Zydus’s DNA vaccine — the world’s first DNA vaccine authorised for Covid, needle free delivery); CORBEVAX (protein-subunit). In other words, india delivered 2+ billion doses through CoWIN — the world’s largest vaccination drive. With Vaccine Maitri exporting ~10 crore doses (see the IR series, Part 8).
• The new platforms. Specifically, gennova’s indigenous mRNA vaccine (thermo stable design). Notably, the pneumococcal and cervical vaccine pipeline; WHO prequalification of a widening Indian portfolio — the “pharmacy of the world” position.
• The biosimilar era. Similarly, the 2024-25 semaglutide patent expiries opened a major biosimilar opportunity for Indian firms — the current commercial story.

3. The Frontier: CAR-T, CRISPR Therapies.

• Overall, india’s first indigenous CAR-T cell therapy (IIT Bombay–Tata Memorial collaboration). Indeed, approved 2024 for certain blood cancers — priced around ₹30-40 lakh against the ₹3-4 crore imported equivalents — the “cell therapy at a tenth of the cost” milestone and a guaranteed current affairs item.
• Consequently, the world’s first approved CRISPR-based medicine (sickle cell disease and beta-thalassemia) — the gene editing therapeutic milestone. Specifically, cost (~₹2-3 crore) keeps accessibility the Indian question.
• Similarly, the National Sickle Cell Anaemia Elimination Mission (2023) — screening ~7 crore people in the tribal belt by 2047 — the programme that pairs with the therapy frontier.
• Stem cells and synthetic biology. Overall, iPSC (Yamanaka) reprogramming for regenerative medicine; Bio-E3’s biofoundries (design-build-test learn infrastructure for engineered biology — biofuels, enzymes, bioplastics); the dual-use biosecurity debate under the BTWC.

4. The Policy Stack: BIRAC and Bio-E3.

• Biotechnology Industry Research Assistance Council (2012, DBT’s PSU) — the startup facilitator. The BIG (Biotechnology Ignition Grant) for idea stage proof-of concept. Biotech startups grew from ~50 (2012) to ~9,000+ (2025) — the 20x in a decade claim.
• The “Biotechnology for Economy, Environment and Employment” policy (Cabinet approved September 2024) — biomanufacturing and biofoundries as the “IT-moment for BT”. Targets the bioeconomy growing from ~$130-150 billion (2024) to $300 billion by 2030 .
• The funding layer. The National Biopharma Mission (2017-24); the 2024 Budget’s ₹1 lakh crore 50-year R&D corpus (Part 6’s detail) partially steers to deep tech bio.

5. The Regulation and Ethics Layer.

• The 1989 rDNA Rules (the GEAC family — see Part 3), the New Drugs and Clinical Trials Rules 2019 (ethics. Compensation), the SDN gene editing exemption discussions. The DPDP Act 2023’s treatment of health/genetic data — the genetic privacy debate around GIP’s controlled access model.
• The ethics line. Somatic editing is permitted; germline editing is globally prohibited (the He Jiankui 2018 case) — India aligns with the WHO’s 2021 governance framework.

6. How Exams Probe This Topic.

• Prelims: GIP (2020; 10,000 genomes; 2025 completion); ZyCoV-D’s first-DNA-vaccine status; NexCAR19 (2024); Casgevy; BIRAC (2012) and the startup count; Bio-E3 (2024); the bioeconomy’s $ figure; the sickle cell mission; NDCT 2019.
• Mains: “Genome India builds the precision medicine foundation — examine the science and the governance needs”. “From Covaxin to NexCAR19, Indian biotech has climbed the value chain — evaluate with the Bio-E3 strategy”. “The bioeconomy’s IT-moment requires talent and capital — discuss the ecosystem gaps.”
• GM regulation (Part 3), R&D funding (Part 6), DPDP (the site’s DPDP notes).

7. Quick Revision: One-Glance Facts.

• 2020 launch; 10,000 genomes (2025); 4,600 population groups; precision medicine base.
• Covaxin-Covishield-ZyCoV-D-CORBEVAX; 2+ bn doses; SII ~60% of global children’s vaccines.
• NexCAR19 (2024, ~₹30-40 lakh); Casgevy (first CRISPR medicine); sickle cell mission (2023/2047).
• BIRAC 2012 (~9,000 startups); Bio-E3 2024; bioeconomy ~$150 bn → $300 bn by 2030.
• NDCT 2019; germline ban; DPDP-health data interface.

The biotech file is a record (the vaccine era), a project (GIP’s completion), a milestone (NexCAR19). A policy (Bio-E3) — held together by the “IT-to BT” narrative. Hold the numbers (10,000 genomes; 9,000 startups; ~$150 bn) and the two frontier cases. Both prelims facts and the mains ecosystem argument are covered.

The Bioeconomy Evidence Pack (Numbers for Mains).

The bioeconomy’s trajectory: ~$10 billion (2014) → ~$130-150 billion (2024-25) → the $300-billion-2030 target under the Bio-E3 and the sector’s roadmaps — a 13x decade with the composition worth knowing: biopharma ~60%-plus of the total. Bio-agri-and industrial biotech the next tranche, and bio-services’ exports the fastest growing line. The employment and startup numbers: the ~9,000-plus biotech startups (from ~50 in 2012), the ~3-lakh plus skilled jobs’ direct employment, and the five-biotech-clusters’ (Bangalore-Hyderabad-Pune-Ahmedabad-Delhi-NCR) concentration. The exam-use: any “bioeconomy” answer opened with this number-set reads as economic-survey-grade. And the critique line that balances it — the R&D-intensity gap (the industry’s formulation-heavy-and discovery light profile), the clinical-trials’ regulatory friction history. The talent and venture depth against the US-China comparators — converts the celebratory into the analytical.

The mRNA and Platform Depth (The Post-COVID Story).

The platform revolution’s Indian chapter: the pandemic proved the platform-vaccine’s speed (the global mRNA-year versus the conventional-decade). India’s response built capability on two tracks — the licensed scale (Covishield’s adenoviral platform at the SII’s volume) and the indigenous-mRNA (Gennova’s thermo stable candidate through its 2022-23 authorisations — the first Indian mRNA platform validated. With the cold-chain lite design the infrastructure constrained markets need). The depth for mains: platforms are the capability (the next outbreak’s answer is a platform and a sequence, not a from scratch programme). The Bio-E3’s biomanufacturing and biofoundry push is the infrastructure layer (the design-build-test learn foundries that the mission funds). And the gap — the platform-IP landscape (the mRNA’s lipid-nanoparticle-patent-thicket) — is where the TRIPS-flexibilities and the patent policy debates (the S&T-Part 7’s file) re enter the biology question. One paragraph connecting Gennova to biofoundries-to patent thickets marks the answer as frontier-aware.

Read next: The Indus Waters Treaty, 1960-2026: Survival, Abeyance and the Exam Questions, Exam-Ready Notes

Related exam guides.

• Black Holes, LIGO and Lagrange Points: Gravitation’s Research Frontier.
• The Indus Waters Treaty, 1960-2026: Survival, Abeyance and the Exam Questions, Exam-Ready Notes.
• Junagadh and the Integration of the Princely States: From the 1948 Plebiscite to the 2025 Supreme Court Verdict, Exam-Ready Notes.

Frequently Asked Questions.

What should you know about 1. The Genome India Project?

Genome India Project (GIP) — launched 2020 by the Department of Biotechnology , a consortium of 20 institutions (IISc Bengaluru coordinating). Goal: whole genome sequencing of 10,000 Indians — the target was completed in early 2025. With the dataset released to researchers through controlled access — the current milestone to cite.

What should you know about 2. The Vaccine Record and Bio-Manufacturing?

Covaxin (Bharat Biotech’s inactivated virus vaccine, co developed with ICMR). Covishield (Serum Institute’s licensed AZ vaccine — SII is the world’s largest vaccine maker, supplying ~60% of global children’s vaccines). ZyCoV-D (Zydus’s DNA vaccine — the world’s first DNA vaccine authorised for Covid, needle free delivery); CORBEVAX (protein-subunit). India delivered 2+ billion doses through CoWIN — the world’s largest vaccination drive. With Vaccine Maitri exporting ~10 crore doses (see the IR series, Part 8).

What should you know about 3. The Frontier: CAR-T, CRISPR Therapies?

India’s first indigenous CAR-T cell therapy (IIT Bombay–Tata Memorial collaboration). Approved 2024 for certain blood cancers — priced around ₹30-40 lakh against the ₹3-4 crore imported equivalents — the “cell therapy at a tenth of the cost” milestone and a guaranteed current affairs item.

What should you know about 4. The Policy Stack: BIRAC and Bio-E3?

Biotechnology Industry Research Assistance Council (2012, DBT’s PSU) — the startup facilitator. The BIG (Biotechnology Ignition Grant) for idea stage proof-of concept. Biotech startups grew from ~50 (2012) to ~9,000+ (2025) — the 20x in a decade claim. The “Biotechnology for Economy, Environment and Employment” policy (Cabinet approved September 2024) — biomanufacturing and biofoundries as the “IT-moment for BT”. Targets the bioeconomy growing from ~$130-150 billion (2024) to $300 billion by 2030 .

What should you know about 5. The Regulation and Ethics Layer?

The 1989 rDNA Rules (the GEAC family — see Part 3), the New Drugs and Clinical Trials Rules 2019 (ethics. Compensation), the SDN gene editing exemption discussions. The DPDP Act 2023’s treatment of health/genetic data — the genetic privacy debate around GIP’s controlled access model.

Related explainers

Environment Part 9: The 500 GW Push — Solar, Wind and Storage

iPhone Price Hike & PLI: Electronics Manufacturing Notes

Gaganyaan G1 & Vyommitra: Human Spaceflight Exam Notes